Literature DB >> 4023472

The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians.

M J Stampfer, J E Buring, W Willett, B Rosner, K Eberlein, C H Hennekens.   

Abstract

The 2 x 2 factorial design calls for randomizing each participant to treatment A or B to address one question and further assignment at random within each group to treatment C or D to examine a second issue, permitting the simultaneous test of two different hypotheses. This design can increase the efficiency of large-scale clinical trials. The Physicians' Health Study, a randomized trial of aspirin and beta-carotene among U.S. physicians, illustrates some features and potential problems in the design and analysis of a factorial trial. The most common concern, interaction between treatments, is generally an advantage rather than a limitation of this design. Although such interactions are relatively uncommon, this design provides a means to measure an effect which otherwise might not be apparent. If the interaction is sufficiently severe, however, then loss of power is possible.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4023472     DOI: 10.1002/sim.4780040202

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  22 in total

1.  Addressing both depression and pain in late life: the methodology of the ADAPT study.

Authors:  Jordan F Karp; Bruce L Rollman; Charles F Reynolds; Jennifer Q Morse; Frank Lotrich; Sati Mazumdar; Natalia Morone; Debra K Weiner
Journal:  Pain Med       Date:  2012-02-07       Impact factor: 3.750

2.  Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies.

Authors:  Federico C F Calboli; David G Cox; Julie E Buring; J Michael Gaziano; Jing Ma; Meir Stampfer; Walter C Willett; Shelley S Tworoger; David J Hunter; Carlos A Camargo; Dominique S Michaud
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

3.  Cancer: improving early detection and prevention. A community practice randomised trial.

Authors:  A J Dietrich; G T O'Connor; A Keller; P A Carney; D Levy; F S Whaley
Journal:  BMJ       Date:  1992-03-14

4.  Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.

Authors:  Kathryn T Hall; Thorsten Kessler; Julie E Buring; Dani Passow; Howard D Sesso; Robert Y L Zee; Paul M Ridker; Daniel I Chasman; Heribert Schunkert
Journal:  Eur Heart J       Date:  2019-11-01       Impact factor: 29.983

Review 5.  Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.

Authors:  Jennifer R Evans; John G Lawrenson
Journal:  Cochrane Database Syst Rev       Date:  2017-07-30

Review 6.  Tantalus revisited--the search for the ideal anti-thrombotic dose of aspirin.

Authors:  D Deykin; J A Jakubowski; M J Stampfer; D Faigel
Journal:  Trans Am Clin Climatol Assoc       Date:  1987

7.  Immunotherapy is different: Implications for vaccine clinical trial design.

Authors:  Richard Simon
Journal:  Hum Vaccin Immunother       Date:  2017-05-12       Impact factor: 3.452

8.  Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome.

Authors:  Barry Kurt Moser; Susan Halabi
Journal:  Commun Stat Theory Methods       Date:  2015       Impact factor: 0.893

9.  Single-nucleotide polymorphisms of allergy-related genes and risk of adult glioma.

Authors:  Danielle M Backes; Afshan Siddiq; David G Cox; Federico C F Calboli; J Michael Gaziano; Jing Ma; Meir Stampfer; David J Hunter; Carlos A Camargo; Dominique S Michaud
Journal:  J Neurooncol       Date:  2013-03-25       Impact factor: 4.130

10.  Simultaneous inference on treatment effects in survival studies with factorial designs.

Authors:  Dan-Yu Lin; Jianjian Gong; Paul Gallo; Paul H Bunn; David Couper
Journal:  Biometrics       Date:  2016-03-17       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.